Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

The venetoclax combined with metronomic low-dose decitabine and interferon for preventing post-transplant relapse in high-risk MDS and AML patients

View Full Paper
Ask AI
Bookmark
Share

Authors

XHXiaobing Huang

Discussion

Loading...

Member takes

Overview

Single-arm study shows venetoclax and interferon reduces relapse in high-risk MDS/AML after HSCT, indicating effective maintenance therapy.

Key Points

  • To evaluate the efficacy and safety of venetoclax and interferon in preventing post-transplant relapse in high-risk MDS and AML patients.
  • Single-center, single-arm retrospective cohort study
  • Included 33 high-risk MDS/AML patients post-allo-HSCT
  • Used venetoclax, decitabine, and interferon as maintenance therapy
  • Median follow-up of 22.0 months; 3 patient deaths and 4 relapses observed
  • 12-month overall survival (OS) was 92.4% and 24-month OS was also 92.4%
  • 12-month event-free survival (EFS) was 88.2% and 24-month EFS was 83.0%
  • 12-month cumulative incidence of relapse was 8.5%; primary adverse events included 69% neutropenia and 41% thrombocytopenia.

Cite This Study

Xiaobing Huang (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2edhttps://doi.org/10.1182/blood-2025-7793
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Defining a Therapeutic Window for Venetoclax in Post‐Transplant Maintenance Therapy for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes2026
  2. 2Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation2025 · 4 citations
  3. 3Low‐dose decitabine plus venetoclax as post‐transplant maintenance for high‐risk myeloid malignancies2024 · 6 citations
  4. 4Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML2025 · 4 citations
  5. 5Azacitidine combined with Venetoclax for pre-emptive treatment of AML/MDS after allogeneic stem cell transplantation: A prospective phase II study2025